Literature DB >> 9061095

Opioids in the brain: supraspinal mechanisms in pain control.

T S Jensen1.   

Abstract

Systemically administered opioids produce a profound inhibition of noxious-evoked activity peripherally, spinally and supraspinally in several species, including man. The role of the brain in opioid mediated-pain control has been less well characterized than that occurring at lower levels in the nervous system. Yet, classical studies indicate that in morphine-induced analgesia the individual senses noxious stimuli, but the affective, motivational and aversive character of the stimulus is no longer present. This observation indicates that morphine probably exerts a specific action on those brain systems that control complex behaviors like aversion and motivation. The failure to document such effects in experimental studies may in part be explained by less suitable methods for assessing antinociception, e.g. measurements of simple reflex behaviors. Experimental animal studies show that supraspinal opioids may influence nociception by several distinct mechanisms, which differ from those seen in the spinal cord: Change of activity in descending bulbospinal pathways. Direct inhibition of noxious throughput at brainstem level. Indirect inhibition of noxious responding brainstem neurons projecting to supraspinal centers. Influence ascending forebrain systems. Direct cortical or thalamic inhibition. In humans, the antinociceptive actions of opioids occurring in the brain has until recently been like looking into a "black box". The introduction of new imaging techniques may provide new tools for directly measuring the antinociceptive action of opioids in the brain under normal and pathological conditions. In particular, the emotional-affective aspect of pain and how this is modulated by opioids will be of interest to study.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9061095     DOI: 10.1111/j.1399-6576.1997.tb04626.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  16 in total

1.  DAMGO in the central amygdala alleviates the affective dimension of pain in a rat model of inflammatory hyperalgesia.

Authors:  R-X Zhang; M Zhang; A Li; L Pan; B M Berman; K Ren; L Lao
Journal:  Neuroscience       Date:  2013-08-28       Impact factor: 3.590

Review 2.  Mechanisms of acupuncture-electroacupuncture on persistent pain.

Authors:  Ruixin Zhang; Lixing Lao; Ke Ren; Brian M Berman
Journal:  Anesthesiology       Date:  2014-02       Impact factor: 7.892

3.  Neurophysiology of Cancer Pain: From the Laboratory to the Clinic.

Authors: 
Journal:  Curr Rev Pain       Date:  1999

4.  The highly selective dopamine D3R antagonist, R-VK4-40 attenuates oxycodone reward and augments analgesia in rodents.

Authors:  Chloe J Jordan; Bree Humburg; Myra Rice; Guo-Hua Bi; Zhi-Bing You; Anver Basha Shaik; Jianjing Cao; Alessandro Bonifazi; Alexandra Gadiano; Rana Rais; Barbara Slusher; Amy Hauck Newman; Zheng-Xiong Xi
Journal:  Neuropharmacology       Date:  2019-04-08       Impact factor: 5.250

5.  Role of Nociceptor Toll-like Receptor 4 (TLR4) in Opioid-Induced Hyperalgesia and Hyperalgesic Priming.

Authors:  Dioneia Araldi; Oliver Bogen; Paul G Green; Jon D Levine
Journal:  J Neurosci       Date:  2019-06-17       Impact factor: 6.167

6.  Ceftriaxone inhibits stress-induced bladder hyperalgesia and alters cerebral micturition and nociceptive circuits in the rat: A multidisciplinary approach to the study of urologic chronic pelvic pain syndrome research network study.

Authors:  Daniel P Holschneider; Zhuo Wang; Huiyi Chang; Rong Zhang; Yunliang Gao; Yumei Guo; Jackie Mao; Larissa V Rodriguez
Journal:  Neurourol Urodyn       Date:  2020-06-23       Impact factor: 2.696

7.  Antinociceptive action of carbamazepine on thermal hypersensitive pain at spinal level in a rat model of adjuvant-induced chronic inflammation.

Authors:  Tatsushige Iwamoto; Yoshihiro Takasugi; Hideaki Higashino; Hiroyuki Ito; Yoshihisa Koga; Shinichi Nakao
Journal:  J Anesth       Date:  2010-11-27       Impact factor: 2.078

8.  Preclinical Testing of Nalfurafine as an Opioid-sparing Adjuvant that Potentiates Analgesia by the Mu Opioid Receptor-targeting Agonist Morphine.

Authors:  Shane W Kaski; Allison N White; Joshua D Gross; Kristen R Trexler; Kim Wix; Aubrie A Harland; Thomas E Prisinzano; Jeffrey Aubé; Steven G Kinsey; Terry Kenakin; David P Siderovski; Vincent Setola
Journal:  J Pharmacol Exp Ther       Date:  2019-09-06       Impact factor: 4.030

9.  Spinal antinociceptive action of loperamide is mediated by opioid receptors in the formalin test in rats.

Authors:  Subrata Basu Ray; Tony L Yaksh
Journal:  Neurosci Lett       Date:  2008-11-01       Impact factor: 3.046

10.  μ-Opioid receptors in primary sensory neurons are involved in supraspinal opioid analgesia.

Authors:  Jie Sun; Shao-Rui Chen; Hui-Lin Pan
Journal:  Brain Res       Date:  2019-12-24       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.